346 related articles for article (PubMed ID: 36831572)
21. Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.
Ma J; Zeng F; Ma C; Pang H; Fang B; Lian C; Yin B; Zhang X; Wang Z; Xia J
Am J Cancer Res; 2016; 6(6):1384-95. PubMed ID: 27429851
[TBL] [Abstract][Full Text] [Related]
22. Chemoresistance in Pancreatic Cancer.
Zeng S; Pöttler M; Lan B; Grützmann R; Pilarsky C; Yang H
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514451
[TBL] [Abstract][Full Text] [Related]
23. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
Yu SJ; Yang L; Hong Q; Kuang XY; Di GH; Shao ZM
BMC Cancer; 2018 Jan; 18(1):74. PubMed ID: 29329575
[TBL] [Abstract][Full Text] [Related]
25. Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Chen Z; Zhao L; Shi K; Chen B
Clin Lab; 2018 May; 64(5):749-757. PubMed ID: 29739052
[TBL] [Abstract][Full Text] [Related]
26. miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.
Yang RM; Zhan M; Xu SW; Long MM; Yang LH; Chen W; Huang S; Liu Q; Zhou J; Zhu J; Wang J
Cell Death Dis; 2017 Oct; 8(10):e3129. PubMed ID: 29048402
[TBL] [Abstract][Full Text] [Related]
27. MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.
Hamada S; Masamune A; Miura S; Satoh K; Shimosegawa T
Cell Signal; 2014 Feb; 26(2):179-85. PubMed ID: 24216611
[TBL] [Abstract][Full Text] [Related]
28. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
29. The Role of MicroRNAs in the Chemoresistance of Breast Cancer.
Wang J; Yang M; Li Y; Han B
Drug Dev Res; 2015 Nov; 76(7):368-74. PubMed ID: 26310899
[TBL] [Abstract][Full Text] [Related]
30. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
31. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Yu S; Wang M; Zhang H; Guo X; Qin R
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
34. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance.
Lee JH; Kim SK; Khawar IA; Jeong SY; Chung S; Kuh HJ
J Exp Clin Cancer Res; 2018 Jan; 37(1):4. PubMed ID: 29329547
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Cancer Chemoresistance to Gemcitabine.
Amrutkar M; Gladhaug IP
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29144412
[TBL] [Abstract][Full Text] [Related]
36. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer.
Huang J; Liu J; Chen-Xiao K; Zhang X; Lee WN; Go VL; Xiao GG
Biomark Res; 2016; 4():20. PubMed ID: 27795830
[TBL] [Abstract][Full Text] [Related]
37. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
[TBL] [Abstract][Full Text] [Related]
38. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
39. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
40. The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.
Choy ATF; Carnevale I; Coppola S; Meijer LL; Kazemier G; Zaura E; Deng D; Giovannetti E
Expert Rev Mol Diagn; 2018 Dec; 18(12):1005-1009. PubMed ID: 30392417
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
